Sign In
Last checked at 
10 Jan 2018 17:09
AMPHION INNOVATIONS PLC
("Amphion" or "the Company")
Directors' Dealings
London and New York, 10 January 2018 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that on 5 January 2018 it granted options over ordinary shares in the Company ("Options") to certain of its directors as follows:
Director | Amount | Strike Price | Vesting |
Richard Mansell-Jones | 563,000 | 1.94 pence | Over one year starting as of 1 August 2017 |
Miroslaw Izienicki | 375,000 | 1.94 pence | Over one year starting as of 1 August 2017 |
All Options commence vesting backdated from 1 August 2017.
The strike price is based on the closing price on 4 January 2018, and the Options are exercisable on the date of vesting. Authority for the allotment of ordinary shares under the Share Option Scheme was approved as a part of the Company's Annual General Meeting.
In addition to the above Options allocation, the Company has issued 799,562 ordinary shares in the Company ("New Ordinary Shares"), representing 0.38% of the enlarged issued share capital, to certain of its Board members (current and former) in payment of directors' fees due them. The issue of Ordinary Shares is calculated based on the closing mid-market price for the five days leading up to the close on 4 January 2018. Following this issue the current directors' shareholdings in the Company are as follows:
Director | Number of New Ordinary Shares | Total Shareholding | Percentage ofVoting Rights |
Miroslaw Izienicki | 193,791 | 795,280 | 0.379% |
Richard Mansell-Jones | 558,896 | 4,344,426 | 2.069% |
Gerard Moufflet (former director) | 46,875 | 1,320,833 | 0.629% |
Admission of the 799,562 New Ordinary Shares, ranking pari passu with the existing ordinary shares, to trading on AIM is expected on 17 January 2018. Following the issue and allotment of the New Ordinary Shares, the total issued share capital of the Company will increase to 209,975,450 ordinary shares with each share holding one voting right. This figure may be used by shareholders in the Company as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Richard Mansell-Jones |
2 | Reason for the notification | |
a) | Position/status | Chairman and PDMR |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Amphion Innovations plc |
b) | LEI | 213800M7MTE2W2P6C104 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument | Ordinary Shares |
b) | Nature of the transaction | Richard Mansell-Jones has received new Ordinary Shares in lieu of fees |
c) | Price(s) and volume(s) | 558,896 Ordinary Shares |
d) | Aggregated information - Aggregated volume - Price |
N/A (Single transaction) |
e) | Date of the transaction | 5 January 2018 |
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Miroslaw Izienicki |
2 | Reason for the notification | |
a) | Position/status | Non-executive Director and PDMR |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Amphion Innovations plc |
b) | LEI | 213800M7MTE2W2P6C104 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument | Ordinary Shares |
b) | Nature of the transaction | Miroslaw Izienicki has received new Ordinary Shares in lieu of fees |
c) | Price(s) and volume(s) | 193,791 Ordinary Shares |
d) | Aggregated information - Aggregated volume - Price |
N/A (Single transaction) |
e) | Date of the transaction | 5 January 2018 |
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name | Richard Mansell-Jones | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chairman and PDMR | ||||
b) | Initial notification/Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Amphion Innovations plc | ||||
b) | LEI | 213800M7MTE2W2P6C104 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument | Options to acquire Ordinary Shares | ||||
b) | Nature of the transaction | Grant of options to acquire Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price |
N/A (Single transaction) | ||||
e) | Date of the transaction | 5 January 2018 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name | Miroslaw Izienicki | ||||
2 | Reason for the notification | |||||
a) | Position/status | Non-executive Director and PDMR | ||||
b) | Initial notification/Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Amphion Innovations plc | ||||
b) | LEI | 213800M7MTE2W2P6C104 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument | Options to acquire Ordinary Shares | ||||
b) | Nature of the transaction | Grant of options to acquire Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price |
N/A (Single transaction) | ||||
e) | Date of the transaction | 5 January 2018 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
For further information please contact:
Amphion Innovations | Tel: +1 (212) 210 6224 | ||||
Charlie Morgan | |||||
Panmure Gordon (UK) Limited (Nominated Adviser and Corporate Broker) | Tel: +44 (0)20 7886 2500 | ||||
Freddy Crossley / Ryan McCarthy (Corporate Finance) | |||||
Charlie Leigh-Pemberton (Corporate Broking) | |||||
Northland Capital Partners Limited (Joint Corporate Broker) | Tel: +44 (0)20 3861 6625 | ||||
Patrick Claridge / David Hignell (Corporate Finance) | |||||
John Howes (Corporate Broking) | |||||
Walbrook PR | Tel: +44 (0)20 7933 8780 or | ||||
Anna Dunphy / Paul McManus | amphion@walbrookpr.com | ||||
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses. We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.
On the web: www.amphionplc.com
Follow the stocks
